Influence of chlorine or fluorine substitution on the estrogenic properties of 1-alkyl-2,3,5-tris(4-hydroxyphenyl)-1H-pyrroles

Journal of Medicinal Chemistry

Volumn 55, Issue 22, 2012, Pages 9607-9618

  Schäfer, Anja ^a   Wellner, Anja ^a   Strauss, Martin ^a   Schäfer, Andreas ^a   Wolber, Gerhard ^a   Gust, Ronald ^a,b  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2,3,5 TRIS(4 HYDROXYPHENYL) 1H PYRROLE DERIVATIVE; 2 (2 CHLORO 4 HYDROXYPHENYL) 3,5 BIS(4 HYDROXYPHENYL) 1 METHYL 1H PYRROLE; 2 (2 CHLORO 4 HYDROXYPHENYL) 3,5 BIS(4 HYDROXYPHENYL) 1 PROPYL 1H PYRROLE; 2 (2 FLUORO 4 HYDROXYPHENYL) 3,5 BIS(4 HYDROXYPHENYL) 1 METHYL 1H PYRROLE; 2 (2 FLUORO 4 HYDROXYPHENYL) 3,5 BIS(4 HYDROXYPHENYL) 1 PROPYL 1H PYRROLE; 2,3,5 TRIS(2 FLUORO 4 HYDROXYPHENYL) 1 PROPYL 1H PYRROLE; 2,5 BIS(2 FLUORO 4 HYDROXYPHENYL) 3 (4 HYDROXYPHENYL) 1 METHYL 1H PYRROLE; 2,5 BIS(2 FLUORO 4 HYDROXYPHENYL) 3 (4 HYDROXYPHENYL) 1 PROPYL 1H PYRROLE; 3 (2 FLUORO 4 HYDROXYPHENYL) 2,5 BIS(4 HYDROXYPHENYL) 1 PROPYL 1H PYRROLE; 5 (2 CHLORO 4 HYDROXYPHENYL) 2,3 BIS(4 HYDROXYPHENYL) 1 METHYL 1H PYRROLE; 5 (2 CHLORO 4 HYDROXYPHENYL) 2,3 BIS(4 HYDROXYPHENYL) 1 PROPYL 1H PYRROLE; 5 (2 FLUORO 4 HYDROXYPHENYL) 2,3 BIS(4 HYDROXYPHENYL) 1 METHYL 1H PYRROLE; 5 (2 FLUORO 4 HYDROXYPHENYL) 2,3 BIS(4 HYDROXYPHENYL) 1 PROPYL 1H PYRROLE; CHLORINE; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FLUORINE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BREAST CANCER; CONTROLLED STUDY; DRUG BINDING; DRUG DETERMINATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ESTROGEN ACTIVITY; SUBSTITUTION REACTION;

BLOTTING, WESTERN; BREAST NEOPLASMS; CELL PROLIFERATION; CHLORINE; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; FLUORINE; HUMANS; LUCIFERASES; MODELS, MOLECULAR; OSTEOSARCOMA; PHENOLS; PROTEIN BINDING; PYRROLES; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 84870047453     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300860j     Document Type: Article

References (42)

1. Silverman, S. L.; Christiansen, C.; Genant, H. K.; Vukicevic, S.; Zanchetta, J. R.; de Villiers, T. J.; Constantine, G. D.; Chines, A. A. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial J. Bone Miner. Res. 2008, 23, 1923-1934
2. Kawate, H.; Takayanagi, R. Efficacy and safety of bazedoxifene for postmenopausal osteoporosis Clin. Interventions Aging 2011, 6, 151-160
3. Crabtree, J. S.; Peano, B. J.; Zhang, X.; Komm, B. S.; Winneker, R. C.; Harris, H. A. Activity of three selective estrogen receptor modulators on hormone-dependent responses in the mouse uterus and mammary gland Mol. Cell. Endocrinol. 2008, 287, 40-46
4. Bardin, A.; Boulle, N.; Lazennec, G.; Vignon, F.; Pujol, P. Loss of ERbeta expression as a common step in estrogen-dependent tumor progression Endocr.-Relat. Cancer 2004, 11, 537-551
5. Park, B.-W.; Kim, K.-S.; Heo, M.-K.; Ko, S.-S.; Lee, K. S.; Hong, S. W.; Yang, W.-I.; Kim, J.-H.; Kim, G. E. Expression of estrogen receptor-β in normal mammary and tumor tissues: Is it protective in breast carcinogenesis? Breast Cancer Res. Treat. 2003, 80, 79-85
6. Gustafsson, J.-Å.; Warner, M. Estrogen receptor β in the breast: role in estrogen responsiveness and development of breast cancer J. Steroid Biochem. Mol. Biol. 2000, 74, 245-248
7. Speirs, V.; Skliris, G. P.; Burdall, S. E.; Carder, P. J. Distinct expression patterns of ERα and ERβ in normal human mammary gland J. Clin. Pathol. 2002, 55, 371-374
8. Hayashi, S.-I.; Eguchi, H.; Tanimoto, K.; Yoshida, T.; Omoto, Y.; Inoue, A.; Yoshida, N.; Yamaguchi, Y. The expression and function of estrogen receptor alpha and beta in human breast cancer and its clinical application Endocr.-Relat. Cancer 2003, 10, 193-202
9. Clarke, R. B.; Howell, A.; Potten, C. S.; Anderson, E. Dissociation between steroid receptor expression and cell proliferation in the human breast Cancer Res. 1997, 57, 4987-4991
10. Fink, B. E.; Mortensen, D. S.; Stauffer, S. R.; Aron, Z. D.; Katzenellenbogen, J. A. Novel structural templates for estrogen-receptor ligands and prospects for combinatorial synthesis of estrogens Chem. Biol. 1999, 6, 205-219
11. Stauffer, S. R.; Coletta, C. J.; Tedesco, R.; Nishiguchi, G.; Carlson, K.; Sun, J.; Katzenellenbogen, B. S.; Katzenellenbogen, J. A. Pyrazole ligands: structure-affinity/activity relationships and estrogen receptor alpha selective agonists J. Med. Chem. 2000, 43, 4934-4947
12. Schäfer, A.; Wellner, A.; Gust, R. Synthesis and investigations on the oxidative degradation of C3/C5-alkyl-1,2,4-triarylpyrroles as ligands for the estrogen receptor ChemMedChem 2011, 6, 794-803
13. Schäfer, A.; Wellner, A.; Strauss, M.; Wolber, G.; Gust, R. Development of 2,3,5-triaryl-1 H -pyrroles as estrogen receptor alpha selective ligands ChemMedChem 2011, 6, 2055-2062
14. Hoffmann, R. Synthese und Pharmakologische Untersuchung Neuer Triaryl-1H-pyrrole mit Estrogenen, Zytotoxischen und COX-Inhibitorischen Eigenschaften. Ph.D. Thesis. Freie Universität Berlin, Berlin, Germany, 2007.
15. Mortensen, D. S.; Rodriguez, A. L.; Carlson, K. E.; Sun, J.; Katzenellenbogen, B. S.; Katzenellenbogen, J. A. Synthesis and biological evaluation of a novel series of furans: ligands selective for estrogen receptor alpha J. Med. Chem. 2001, 44, 3838-3848
16. Wyvratt, J. M.; Hazen, G. G.; Weinstock, L. M. A convenient, general synthesis of alpha-trichloro-methyl carbinols J. Org. Chem. 1987, 52, 944-945
17. Cafiero, L. R.; Snowden, T. S. General and practical conversion of aldehydes to homologated carboxylic acids Org. Lett. 2008, 10, 3853-3856
18. Oki, M. Applications of Dynamic NMR Spectroscopy to Organic Chemistry; VCH Publishers: Deerfield Beach, FL, 1985; Vol. 4, p 423.
19. Oki, M. The Chemistry of Rotational Isomers; Springer: Berlin, Germany, 1993; Vol. 30, p 172.
20. Hafner, F.; Holler, E.; von Angerer, E. Effect of growth factors on estrogen receptor mediated gene expression J. Steroid Biochem. Mol. Biol. 1996, 58, 385-393
21. Meyer, T.; Koop, R.; von Angerer, E.; Schönenberger, H.; Holler, E. A rapid luciferase transfection assay for transcription activation effects and stability control of estrogenic drugs in cell cultures J. Cancer Res. Clin. Oncol. 1994, 120, 359-364
22. Laïos, I.; Cleeren, A.; Leclercq, G.; Nonclercq, D.; Laurent, G.; Schlenk, M.; Wellner, A.; Gust, R. Effects of (R, S)/(S, R)-4,5-bis(2-chloro-4- hydroxyphenyl)-2-imidazolines and (R, S)/(S, R)-2,3-bis(2-chloro-4- hydroxyphenyl)piperazines on estrogen receptor alpha level and transcriptional activity in MCF-7 cells Biochem. Pharmacol. 2007, 74, 1029-1038
23. Watts, C. K. W.; King, R. J. B. Overexpression of estrogen receptor in HTB 96 human osteosarcoma cells results in estrogen-induced growth inhibition and receptor cross talk J. Bone Miner. Res. 1994, 9, 1251-1258
24. Wiglenda, T.; Gust, R. Structure-activity relationship study to understand the estrogen receptor-dependent gene activation of aryl- and alkyl-substituted 1 H -imidazoles J. Med. Chem. 2007, 50, 1475-1484
25. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking J. Mol. Biol. 1997, 267, 727-748
26. Bruning, J. B.; Parent, A. A.; Gil, G.; Zhao, M.; Nowak, J.; Pace, M. C.; Smith, C. L.; Afonine, P. V.; Adams, P. D.; Katzenellenbogen, J. A.; Nettles, K. W. Coupling of receptor conformation and ligand orientation determine graded activity Nat. Chem. Biol. 2010, 6, 837-843
27. Fang, J.; Akwabi-Ameyaw, A.; Britton, J. E.; Katamreddy, S. R.; Navas, F., 3rd; Miller, A. B.; Williams, S. P.; Gray, D. W.; Orband-Miller, L. A.; Shearin, J.; Heyer, D. Synthesis of 3-alkyl naphthalenes as novel estrogen receptor ligands Bioorg. Med. Chem. Lett. 2008, 18, 5075-5077
28. Shiau, A. K.; Barstad, D.; Loria, P. M.; Cheng, L.; Kushner, P. J.; Agard, D. A.; Greene, G. L. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen Cell 1998, 95, 927-937
29. Rajan, S. S.; Kim, Y.; Vanek, K.; Joachimiak, A.; Greene, G. L. Crystal structure of human estrogen receptor alpha ligand-binding domain in complex with a glucocorticoid receptor interacting protein 1 nr box II peptide and estra-1,3,5(10)-triene-3,15 alpha,16alpha,17beta-tetrol. To be published.
30. Mewshaw, R. E.; Bowen, S. M.; Harris, H. A.; Xu, Z. B.; Manas, E. S.; Cohn, S. T. ERbeta ligands. Part 5: synthesis and structure-activity relationships of a series of 4′-hydroxyphenyl-aryl-carbaldehyde oxime derivatives Bioorg. Med. Chem. Lett. 2007, 17, 902-906
31. Richardson, T. I.; Dodge, J. A.; Wang, Y.; Durbin, J. D.; Krishnan, V.; Norman, B. H. Benzopyrans as selective estrogen receptor beta agonists (SERBAs). Part 5: Combined A- and C-ring structure-activity relationship studies Bioorg. Med. Chem. Lett. 2007, 17, 5563-5566
32. Möcklinghoff, S.; Rose, R.; Carraz, M.; Visser, A.; Ottmann, C.; Brunsveld, L. Synthesis and crystal structure of a phosphorylated estrogen receptor ligand binding domain ChemBioChem 2010, 11, 2251-2254
33. Stauffer, S. R.; Huang, Y.; Coletta, C. J.; Tedesco, R.; Katzenellenbogen, J. A. Estrogen pyrazoles: defining the pyrazole core structure and the orientation of substituents in the ligand binding pocket of the estrogen receptor Bioorg. Med. Chem. 2001, 9, 141-150
34. Karl, J.; Gust, R.; Spruss, T.; Schneider, M. R.; Schoenenberger, H.; Engel, J.; Wrobel, K. H.; Lux, F.; Haeberlin, S. T. Ring-substituted [1,2-bis(4-hydroxyphenyl)ethylenediamine]dichloroplatinum(II) complexes: compounds with a selective effect on the hormone-dependent mammary carcinoma J. Med. Chem. 1988, 31, 72-83
35. Gust, R.; Keilitz, R.; Schmidt, K. Synthesis, structural evaluation, and estrogen receptor interaction of 2,3-diarylpiperazines J. Med. Chem. 2002, 45, 2325-2337
36. Gust, R.; Keilitz, R.; Schmidt, K.; von Rauch, M. (4 R,5 S)/(4 S,5 R)-4,5-Bis(4-hydroxyphenyl)-2-imidazolines: ligands for the estrogen receptor with a novel binding mode J. Med. Chem. 2002, 45, 3356-3365
37. Sadowski, J.; Gasteiger, J.; Klebe, G. Comparison of automatic three-dimensional model builders using 639 X-ray structures J. Chem. Inf. Comput. Sci. 1994, 34, 1000-1008
38. Goebel, M.; Wolber, G.; Markt, P.; Staels, B.; Unger, T.; Kintscher, U.; Gust, R. Characterization of new PPAR[gamma] agonists: benzimidazole derivatives - importance of positions 5 and 6, and computational studies on the binding mode Bioorg. Med. Chem. 2010, 18, 5885-5895
39. Wolber, G.; Langer, T. LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters J. Chem. Inf. Model. 2005, 45, 160-169
40. Wolber, G.; Dornhofer, A. A.; Langer, T. Efficient overlay of small organic molecules using 3D pharmacophores J. Comput.-Aided Mol. Des. 2006, 20, 773-788
41. Wolber, G.; Seidel, T.; Bendix, F.; Langer, T. Molecule-pharmacophore superpositioning and pattern matching in computational drug design Drug Discovery Today 2008, 13, 23-29
42. El Khissiin, A.; Journe, F.; Laios, I.; Seo, H. S.; Leclercq, G. Evidence of an estrogen receptor form devoid of estrogen binding ability in MCF-7 cells Steroids 2000, 65, 903-913